Xtant Medical (XTNT) Investor presentation summary

Strategic focus and market opportunity

• Emphasis on high-margin orthobiologics, targeting a $4B US market and $10B+ in adjacent sectors.

• Exclusive US distribution agreement for HEMOBLAST expands reach into the $1B hemostatic biologics market.

• Sale of non-core assets to Companion Spine enhanced cash position and reduced long-term debt by nearly 50%.

• Vertically integrated manufacturing improves margins and supply chain control.

• Broad commercial reach with ~450 hospital system contracts and over 500 independent distributors.

Product portfolio and innovation

• Comprehensive biologics and fixation offerings address diverse physician and patient needs.

• Only orthobiologics company manufacturing all five major product categories.

• Recent launches include SimpliMax, OsteoVive Plus, Trivium, FibreX, NanOss Strata, OsteoFactor Pro, and CollagenX.

• Development pipeline targets premium, clinically validated products and adjacent markets.

• Focus on innovation and margin expansion through next-generation DBM and proprietary technologies.

Financial performance and outlook

• Achieved robust revenue growth from $51M in FY2020 to $134M in FY2025, with 14% organic YoY growth.

• Q2 2026 revenue declined due to asset sales and changes in reimbursement, with gross margin at 58%.

• Adjusted EBITDA turned negative in 2026 following asset divestitures and strategic investments.

• Cash position strengthened post-asset sale, though operating cash flow turned negative in 2026.

• Strategic focus on profitability through scaling, branded product sales, and OEM growth.